ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary

ADC Therapeutics SA

06/05/2021 18:41

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss of 46 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 90 cents per share.
* Revenue was $0.00​​;  analysts expected $94.33 thousand.
* ADC Therapeutics SA's reported EPS for the quarter was a loss
of 67 cents​.
* The mean earnings estimate of analysts had fallen by
about 22.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* ADC Therapeutics SA shares had fallen by 9.9% this quarter and
lost 31.3% so far this year.
* The company reported a quarterly loss of $51.53 million.
* Wall Street's median 12-month price target for ADC
Therapeutics SA is $55.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 05:41 p.m. GMT. ​All
figures in US Dollars.​